secwatch.observer — SEC 8-K summary
======================================

Issuer:     Krystal Biotech, Inc. (KRYS)
CIK:        0001711279
Form:       8-K
Filed at:   2023-05-19T23:59:59+00:00
Accession:  0001711279-23-000037
Event type: regulatory
Sentiment:  positive
Materiality: 0.95
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA approves Krystal Biotech's VYJUVEK gene therapy for DEB; first redosable gene therapy
--------------------------------------------------------------------------------

- FDA approval of VYJUVEK (beremagene geperpavec-svdt) for dystrophic epidermolysis bullosa (DEB) patients aged 6 months+.
- Phase 3 GEM-3 trial met primary endpoint of complete wound healing at six months and key secondary endpoint at three months.
- First-ever redosable gene therapy approved and first FDA-approved medicine for DEB (both recessive and dominant).
- Rare Pediatric Disease Priority Review Voucher granted by FDA.
- U.S. commercial launch expected Q3 2023; EU filing planned H2 2023, Japan launch targeted 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711279/000171127923000037/0001711279-23-000037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711279/000171127923000037/krys-20230519.htm
  HTML page:      https://secwatch.observer/filing/0001711279-23-000037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer